ZFP82 and neoplasm: In addition, in vivo data demonstrate decreased tumor growth upon reexpression of ZNF545. Together with the observation that ZNF545 promoter methylation correlates with poorer clinical outcomes, these data highlight the TSG function of ZNF545 in multiple malignancies [72,74,75,77].